The launch of AI-powered imaging and mapping capabilities in electrophysiology, early momentum for a drug release system for bladder cancer, and progress toward an integrated benchtop robotic surgical system are among the latest innovations from the pharmaceutical company and MedTech. Johnson & Johnson.
Johnson & Johnson Chairman and CEO Joaquin Duato These products were highlighted on Wednesday (July 15) during the company’s second quarter Earnings call.
“Our progress in the second quarter reflects what makes Johnson & Johnson unique, a company that innovates across the full spectrum of health care, delivering strong performance today while building a pipeline that will transform care for patients tomorrow,” Duato said. “As we look to the future, our confidence is rooted in the breadth of our innovations, from transformative medicines to next-generation medical technologies.”
Last April, Johnson & Johnson announced the launch of… Cartosound SonataHe was bringing something new Artificial intelligence-based imaging and mapping capabilities of electrophysiology. This tool uses artificial intelligence to create maps that help doctors build accurate models of the heart’s multiple chambers and to help doctors treat a range of heart rhythm conditions.
Duato said during a call on Wednesday that this tool provides new capabilities and strengthens the company’s position in MedTech.
The company announced in September 2025 that it had acquired… Food and Drug Administration FDA approval inlexzoA Drug release system Which provides extended local delivery of cancer drugs to the bladder. Johnson & Johnson said at the time in a press release that the regimen provided a “potential practice-changing treatment” for some patients.
During Wednesday’s call, Duato said Johnson & Johnson is “encouraged by the early momentum” of product sales.
Duato also highlighted an integrated robotic surgical system called eighthSaying that Johnson & Johnson is moving toward potential FDA authorization of this system and that the system “is one of the most important MedTech innovations we will bring to market this decade.”
“In surgery, we are opening a new era powered by robotics and digital innovation,” Duato said during the call.
During the second quarter, Johnson & Johnson saw operating sales grow 5.6% to $25.3 billion, with its innovative medicine business rising 6.8% to $16.4 billion, and its medical technology business increasing 3.6% to $8.9 billion, according to a statement Wednesday. Earnings release.
The company has raised its guidance and expects its annual revenues to exceed $100 billion this year, for the first time in Johnson & Johnson’s 140-year history, Duato said.
